{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:16:08Z","timestamp":1791353768668,"version":"4.3.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.clml.2016.06.012","type":"journal-article","created":{"date-parts":[[2016,6,21]],"date-time":"2016-06-21T06:24:43Z","timestamp":1466490283000},"page":"488-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions"],"prefix":"10.1016","volume":"16","author":[{"given":"Sheena","family":"Bhalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2584-6953","authenticated-orcid":false,"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.06.012_bib1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","article-title":"Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management","volume":"89","author":"Jabbour","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2016.06.012_bib2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.06.012_bib3","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"Paper: international randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.06.012_bib5","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.06.012_bib6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.V124.21.152.152","article-title":"Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056)","volume":"124","author":"Cortes","year":"2014","journal-title":"Blood"},{"issue":"15Suppl","key":"10.1016\/j.clml.2016.06.012_bib7","first-page":"7052","article-title":"Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update","volume":"31","author":"Larson","year":"2013","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.clml.2016.06.012_bib8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","article-title":"Deep molecular response in chronic myeloid leukemia: the new goal of therapy?","volume":"20","author":"Mahon","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2016.06.012_bib10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib11","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood.V124.21.4541.4541","article-title":"Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f\/u) of ENESTnd","volume":"124","author":"Larson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11899-016-0306-5","article-title":"Quality of life and long-term therapy in patients with chronic myeloid leukemia","volume":"11","author":"Flynn","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"Supp2","key":"10.1016\/j.clml.2016.06.012_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00277-015-2317-z","article-title":"Managing pregnancy in chronic myeloid leukaemia","volume":"94","author":"Palani","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2016.06.012_bib14","first-page":"607","article-title":"Fertility in male patients with (chronic phase) chronic myeloid leukemia receiving tyrosine kinase inhibitors as first line of therapy","volume":"607","author":"Yassin","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.06.012_bib15","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib17","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/asheducation.V2012.1.122.3798214","article-title":"Is going for cure in chronic myeloid leukemia possible and justifiable?","volume":"2012","author":"Mahon","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2016.06.012_bib18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2016.06.012_bib19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/blood.V122.21.255.255","article-title":"Long-term follow-up after imatinib cessation for patients in deep molecular response: the update results of the STIM1 study","volume":"122","author":"Rea","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.06.012_bib22","doi-asserted-by":"crossref","first-page":"e11770","DOI":"10.1371\/journal.pone.0011770","article-title":"PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal","volume":"5","author":"Kanodia","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2016.06.012_bib23","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood.V122.21.4020.4020","article-title":"Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib","volume":"122","author":"Nicolini","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood.V124.21.151.151","article-title":"Interim analysis of a Pan-European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: the EURO-SKI study","volume":"124","author":"Mahon","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib25","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?","volume":"32","author":"Richter","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.06.012_bib26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.06.012_bib27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V124.21.811.811","volume":"124","author":"Rea","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib28","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood.V126.23.4029.4029","article-title":"Treatment-free remission (TFR) eligibility in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) and residual disease on long-term imatinib (IM) who switched to second-line nilotinib (NIL)","volume":"126","author":"Hughes","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib29","unstructured":"Open-label study evaluating dasatinib therapy discontinuation in patients with chronic phase chronic myeloid leukemia with stable complete molecular response. 2016. Available at: https:\/\/clinicaltrials.gov\/show\/NCT01850004. Accessed: March 18, 2016. NLT Identifier: NCT01850004."},{"key":"10.1016\/j.clml.2016.06.012_bib30","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3109\/10428194.2013.831092","article-title":"Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience","volume":"55","author":"Benjamini","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.06.012_bib31","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib32","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood-2013-06-508465","volume":"122","author":"Dulphy","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood.V122.21.379.379","article-title":"Disease relapse after TKI discontinuation in CML is related both to low number and impaired function of NK-cells: data from Euro-SKI","volume":"122","author":"Olsson-Str\u00f6mberg","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.012_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","article-title":"Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?","volume":"47","author":"Goldman","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.06.012_bib35","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3324\/haematol.2012.062844","article-title":"Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials","volume":"97","author":"Tang","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.06.012_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/asheducation-2013.1.189","article-title":"Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond","volume":"2013","author":"Ahmed","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2016.06.012_bib37","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.3747\/co.21.1736","article-title":"Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"21","author":"Sanford","year":"2014","journal-title":"Curr Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016301173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016301173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:23Z","timestamp":1761870443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016301173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S2152265016301173"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.06.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}